Europe

Oxford Immunotec Global PLC today announced that it plans to release third quarter 2018 financial results prior to market open on Friday, November 9, 2018.

According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of the Nomination Committee for the 2019 Annual General Meeting shall be appointed through a procedure where the three largest shareholders in terms of voting power according to Euroclear’s transcription of the share register as of September 30, 2018 are contacted by the Chairman of the Board and asked to appoint one representative each to the Nomination Committee.

New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD

Polarean Imaging plc provides shareholders with the following update on Company progress:

First-in-class enterprise workflow platform for streamlining cell line development operations

iTeos Therapeutics SA today announced the presentation of two posters on its novel A2A receptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, taking place from November 7-11, 2018 in Washington, D.C.

Evonik has become the first company in the world to develop a polymer filament based on PEEK (polyether ether ketone) in implant-grade quality for use as a 3D printing material for implants.

BerGenBio ASA will announce its results for the third quarter 2018 on Tuesday, 13 November 2018.

ProBioGen AG announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded expectations.

Physician from Karl Landsteiner University of Health Sciences plays a part in global consensus-building process